Mylan Recalls Mirtazapine Tablets Due to Foreign Glipizide Contamination
Mylan Institutional is recalling Mirtazapine 45 mg tablets because they may contain foreign Glipizide 10 mg tablets.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric, particularly given the risk of administering the wrong medication (Glipizide instead of Mirtazapine).
Plain-English summary
Mylan Institutional, Inc. (d.b.a. UDL Laboratories) is recalling Mirtazapine Tablets, USP, 45 mg. The recall involves 58 UD100 Unit Dose Blister Cards of 10 tablets each, identified by Batch #3083289 and an expiration date of 12/2018. The product is distributed nationwide.
The recall was initiated due to the presence of foreign tablets or capsules, specifically the possibility that Glipizide 10 mg tablets are commingled with the Mirtazapine tablets. This contamination poses a risk of patients receiving an incorrect medication.
Patients and healthcare providers should discontinue use of the affected Mirtazapine tablets and contact their healthcare provider for appropriate medical evaluation and alternative treatment options. The recalling firm is responsible for managing the recall and providing further instructions to affected parties.
The recalled product
- Product
- MIRTAZAPINE (MIRTAZAPINE)
- Brand
- MIRTAZAPINE
- Category
- Drug — Prescription Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Batch #3083289
- Exp. Date 12/2018
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · MIRTAZAPINE
- ModerateAurobindo Recalls Mirtazapine Tablets Due to Manufacturing Water Leakage
FDA (Drugs) · 2020-04-22
- SevereAuroMedics Recalls Mirtazapine Tablets Due to Labeling Error
FDA (Drugs) · 2019-12-18
- ModerateAuroMedics Recalls Mirtazapine Tablets Due to Labeling Error
FDA (Drugs) · 2019-12-18
- SevereMylan Recalls Mirtazapine Tablets Due to Foreign Glipizide Contamination
FDA (Drugs) · 2017-03-15
Same manufacturer · Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
See all →- ModerateEsomeprazole Magnesium Delayed-Release Capsules Recalled for Failed Quality Specifications
FDA (Drugs) · 2022-05-18
- HighEsomeprazole magnesium delayed-release capsules recalled for impurity specification failure
FDA (Drugs) · 2022-05-18
- SevereMylan Recalls Alprazolam Tablets Due to Elevated Impurity Levels
FDA (Drugs) · 2019-03-27
- LowMylan Recalls Diltiazem HCl Extended-release Capsules Due to Impurities
FDA (Drugs) · 2018-08-29
- ModerateMylan Recalls Loxapine Capsules Due to Cross-Contamination Risk
FDA (Drugs) · 2018-05-30
Same hazard · foreign object
See all →- SevereOutshine Strawberry Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Black Cherry Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Fruit Bars Grape Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02
- SevereOutshine Watermelon Fruit Bars Recalled for Potential Glass Contamination
FDA (Food) · 2026-09-02